幹細胞治療市場 : 2028年までの世界予測

Report Overview

The global stem cell therapy market is projected to reach USD 615 million by 2028 from USD 286 million in 2023, at a CAGR of 16.5% during the forecast period. Key market players are focusing on developing new stem cell therapies for various disease conditions this is one of the major factor is likely to impact the market growth in coming years. The increasing number of clinical trials has largely in past few years coupled with rise in FDA approvals for stem cell therapy is anticipated to give momentum to the market growth.

“The allogeneic stem cell segment accounted dominant share in 2022”
The stem cell therapy market is segmented into allogeneic and autologous. Allogeneic segment accounted for the dominant share in 2022. In allogeneic stem cell therapy, one cell source can produce numerous doses, thus making allogeneic therapy economically viable and less time-consuming, these are some of the major elements responsible for the doninat share of the segment. Presently, more than ten approved commercialized allogeneic stem cell therapies are available globally.

“Bone Marrow-derived MSCs segment is anticipated to grow at significant CAGR”
Based on the cell source the global stem cell therapy market is segmented into adipose tissue-derived MSCs, bone marrow-derived MSCs, placenta/umbilical cord-derived MSCs, and other cell sources. In 2022, the adipose tissue-derived MSCs segment gained dominant share in the stem cell therapy market. Bone marrow-derived mesenchymal stem cells most preferred type for are stem cell therapies. Easy availability of Bone marrow MSCs and less time required for in-vitro processing are some of the major factorslikely to give momentum to the use of bone marrow derived MSCs uplifting the segmental growth.

“Asia Pacific region is likely to grow at a faster pace.”
The stem cell therapy market is segmented into North America, Europe, Asia Pacific and Rest of the world. Asia Pacific region is anticipated to grow at a significant CAGR during the forecast period. Rising approvals from the government for stem cell therapy in South Korea. Furthermore, industrial collabrations in the region for stem cell therapy development is further likely to give pace for the market growth in the region. For instance, Reyon Pharmaceutical and Therabest entered into a joint development agreement for NK cell therapy for treating solid cancer. Under this agreement, the two companies will jointly develop iPSC (induced pluripotent stem cell)-derived NK cell therapy ‘TB-100’ for solid cancer indications.

The primary interviews conducted for this report can be categorized as follows:
• By Respondent: Supply Side- 80%, and Demand Side – 20%
• By Designation (Supply Side): Managers – 45%, CXOs & Directors – 30%, Executives- 25%
• By Region: North America -40%, Asia-Pacific -20%, Europe -30%,  ROW-10%
List of Companies Profiled in the Report:
• Smith+Nephew (UK)
• MEDIPOST Co. Ltd. (South Korea)
• Anterogen Co. Ltd. (South Korea)
• CORESTEM (South Korea)
• Pharmicell Co. Ltd. (South Korea)
• NuVasive Inc. (US)
• RTI Surgical (US)
• AlloSource (US)
• JCR Pharmaceuticals Co. Ltd. (Japan)
• Takeda Pharmaceutical Company Limited (Japan)
• Holostem Terapie Avanzate Srl (Italy)
• Orthofix (US)
• Regrow Biosciences Pvt Ltd. (India)
• STEMPEUTICS RESEARCH PVT LTD. (India)
• Athersys (US)
• Mesoblast Ltd (Australia)
• Biorestorative Therapies Inc. (US)
• Pluristem Inc. (Israel)
• Brainstorm Cell Limited. (US)
• ViaCyte Inc. (US)
• Gamida Cell (US)
• Kangstem Biotech (South Korea)
• Hope Biosciences (US)
• Cellular Biomedicine Group (US)
• Personalized Stem Cells (US)

Research Coverage:
This report provides a detailed picture of the stem cell therapy market. It aims to estimate the size and future growth potential of the market across different segments, such as such as the type, therapeutic applications, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall stem cell therapy market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:
• Analysis of key drivers (Increased funding for stem cell research, rise in collabrations and partnerships is likley to uplift the market growth,  Increasing clinical trials for stem cell based-therapies), restraints ( Ethical concerns related to embryonic stem cells, high cost of cell-based research), opportunities (The emergence of iPSCs as an alternative to ESCs, growing demand for stem cell and gene therapy) and challenges (Technical limitations) are influencing the growth of stem cell therapy market.
• Product Development/Innovation: Detailed insights on newly launched products of the stem cell therapy market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the stem cell therapy market across varied regions.
• Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the stem cell therapy market.
• Pipeline Analysis: Detailed information on stem cell therapy under phase 3 clinical trials.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players include Smith+Nephew (UK), MEDIPOST Co. Ltd. (South Korea), Anterogen Co. Ltd. (South Korea), CORESTEM (South Korea) and among others in the stem cell therapy market.

Table of Contents

1            INTRODUCTION            28

1.1         STUDY OBJECTIVES      28

1.2         MARKET DEFINITION   28

1.3         INCLUSIONS & EXCLUSIONS     29

1.4         MARKET SCOPE             29

1.4.1      MARKETS COVERED     29

1.4.2      YEARS CONSIDERED     30

1.5         CURRENCY        30

1.6         RESEARCH LIMITATIONS           30

1.7         STAKEHOLDERS            31

1.8         SUMMARY OF CHANGES            31

1.9         RECESSION IMPACT      32

2            RESEARCH METHODOLOGY     33

2.1         RESEARCH DATA           33

FIGURE 1           RESEARCH DESIGN       33

2.1.1      SECONDARY DATA       34

2.1.2      PRIMARY DATA 35

FIGURE 2           BREAKDOWN OF PRIMARIES: STEM CELL THERAPY MARKET              35

2.2         MARKET SIZE ESTIMATION       36

FIGURE 3           MARKET SIZE ESTIMATION FOR SUPPLY-SIDE ANALYSIS, 2022              36

FIGURE 4           MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2022              37

FIGURE 5           SMITH+NEPHEW: REVENUE SHARE ANALYSIS, 2022       37

2.2.1      PRIMARY INSIGHTS       38

FIGURE 6           VALIDATION FROM PRIMARY EXPERTS 38

2.2.2      SEGMENT ASSESSMENT METHODOLOGY: STEM CELL THERAPY MARKET            39

FIGURE 7           MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH       39

FIGURE 8           CAGR PROJECTIONS: STEM CELL THERAPY MARKET    40

FIGURE 9           GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES  40

2.3         MARKET BREAKDOWN AND DATA TRIANGULATION    41

FIGURE 10         DATA TRIANGULATION METHODOLOGY         41

2.4         STUDY ASSUMPTIONS  42

2.5         RISK ANALYSIS 42

2.6         IMPACT OF RECESSION ON STEM CELL THERAPY MARKET       43

TABLE 1             GLOBAL INFLATION RATE PROJECTION, 2024–2028 (% GROWTH)         43

TABLE 2             US HEALTH EXPENDITURE, 2019–2022 (USD MILLION)  43

TABLE 3             US HEALTH EXPENDITURE, 2023–2027 (USD MILLION)  44

3            EXECUTIVE SUMMARY 45

FIGURE 11         STEM CELL THERAPY MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)          45

FIGURE 12         STEM CELL THERAPY MARKET, BY CELL SOURCE, 2023 VS. 2028 (USD MILLION) 46

FIGURE 13         STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2023 VS. 2028 (USD MILLION)     46

FIGURE 14         REGIONAL SNAPSHOT OF STEM CELL THERAPY MARKET              47

4            PREMIUM INSIGHTS      49

4.1         STEM CELL THERAPY MARKET OVERVIEW        49

FIGURE 15         INCREASING INVESTMENTS AND FUNDING FOR STEM CELL RESEARCH TO DRIVE MARKET 49

4.2         NORTH AMERICA: STEM CELL THERAPY MARKET, BY TYPE AND COUNTRY, 2022 50

FIGURE 16         ALLOGENEIC STEM CELL THERAPY ACCOUNTED FOR LARGEST MARKET SHARE IN 2022          50

4.3         STEM CELL THERAPY MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES           51

FIGURE 17         SOUTH KOREA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD     51

5            MARKET OVERVIEW     52

5.1         INTRODUCTION            52

5.2         MARKET DYNAMICS     52

FIGURE 18         STEM CELL THERAPY MARKET: DRIVERS, RESTRAINTS,

OPPORTUNITIES, AND CHALLENGES    52

5.2.1      DRIVERS            53

5.2.1.1   Increased funding for stem cell research        53

TABLE 4             FUNDING FOR STEM CELL RESEARCH BY INDIAN COUNCIL OF MEDICAL RESEARCH, 2019–2022 (USD)  53

TABLE 5             FUNDING FOR CELL-BASED RESEARCH BY NATIONAL INSTITUTES OF HEALTH, 2018–2023 (USD MILLION)      53

5.2.1.2   Rising number of collaborations among healthcare institutes     54

5.2.1.3   Increasing number of clinical trials for stem cell-based therapies              55

FIGURE 19         NUMBER OF CLINICAL TRIALS, 2015–2022          55

5.2.2      RESTRAINTS     56

5.2.2.1   Ethical concerns related to use of embryonic stem cells 56

5.2.2.2   High cost of cell-based research and stem cell therapy 56

5.2.3      OPPORTUNITIES           57

5.2.3.1   Increased availability of alternatives to embryonic stem cells      57

5.2.3.2   Growing demand for cell and gene therapies  58

5.2.4      CHALLENGES   58

5.2.4.1   Technological limitations   58

5.3         TECHNOLOGY ANALYSIS           59

TABLE 6             COMPARISON BETWEEN STEM CELL THERAPIES AND GENE THERAPIES       59

5.4         DISRUPTIONS AND TRENDS IMPACTING CUSTOMER’S BUSINESS              60

FIGURE 20         REVENUE SHIFT AND NEW POCKET FOR KEY PLAYERS IN STEM CELL THERAPY MARKET 60

5.5         VALUE CHAIN ANALYSIS            60

FIGURE 21         STEM CELL THERAPY MARKET: VALUE CHAIN ANALYSIS              61

5.6         ECOSYSTEM MARKET MAP        61

FIGURE 22         STEM CELL THERAPY MARKET: ECOSYSTEM MARKET MAP              61

5.7         SUPPLY CHAIN ANALYSIS          62

FIGURE 23         STEM CELL THERAPY MARKET: SUPPLY CHAIN ANALYSIS              62

TABLE 7             SUPPLY CHAIN ANALYSIS: ROLE OF COMMERCIAL-SCALE/KEY MANUFACTURERS        63

TABLE 8             SUPPLY CHAIN ANALYSIS: PIPELINE/EMERGING MANUFACTURERS        63

5.8         PORTER’S FIVE FORCES ANALYSIS         64

5.8.1      THREAT OF NEW ENTRANTS    64

5.8.2      THREAT OF SUBSTITUTES         64

5.8.3      BARGAINING POWER OF SUPPLIERS     64

5.8.4      BARGAINING POWER OF BUYERS           65

5.8.5      INTENSITY OF COMPETITION RIVALRY 65

5.9         REGULATORY ANALYSIS            65

5.9.1      REGULATORY LANDSCAPE       65

5.9.1.1   North America     65

TABLE 9             NORTH AMERICA: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES       65

5.9.1.2   Europe  68

TABLE 10           EUROPE: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES       68

5.9.1.3   Asia Pacific          69

TABLE 11           ASIA PACIFIC: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES       69

5.9.1.4   Rest of the World 71

TABLE 12           REST OF THE WORLD: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES           71

5.9.2      REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS          72

TABLE 13           NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         72

TABLE 14           EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 72

TABLE 15           ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         74

TABLE 16           REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         75

5.10       PRICING ANALYSIS        75

5.10.1    PRICING ANALYSIS        75

TABLE 17           AVERAGE SELLING PRICE OF DRUG THERAPIES OFFERED BY KEY PLAYERS IN STEM CELL THERAPY MARKET             75

5.10.2    AVERAGE SELLING PRICE TREND FOR STEM CELL THERAPIES 76

5.11       PATENT ANALYSIS        77

FIGURE 24         STEM CELL THERAPY: PATENT ANALYSIS, 2013–2023     77

5.12       KEY CONFERENCES & EVENTS  78

TABLE 18           LIST OF KEY CONFERENCES & EVENTS, 2023–2024          78

5.13       PIPELINE ANALYSIS      78

5.14       KEY STAKEHOLDERS & BUYING CRITERIA          81

FIGURE 25         KEY STAKEHOLDERS    81

5.14.1    KEY BUYING CRITERIA 82

FIGURE 26         KEY BUYING CRITERIA FOR END USERS              82

6            STEM CELL THERAPY MARKET, BY CELL SOURCE          83

6.1         INTRODUCTION            84

TABLE 19           STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021–2028 (USD MILLION) 84

6.2         ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS           84

6.2.1      EASE OF ISOLATION AND HARVESTING TO DRIVE GROWTH    84

TABLE 20           ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS MARKET, BY REGION, 2021–2028 (USD MILLION)            85

TABLE 21           NORTH AMERICA: ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)             85

TABLE 22           EUROPE: ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)          86

TABLE 23           ASIA PACIFIC: ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)             86

6.3         BONE MARROW-DERIVED MESENCHYMAL STEM CELLS             86

6.3.1      HIGH PREVALENCE OF METABOLIC DISORDERS TO SUPPORT MARKET GROWTH        86

TABLE 24           BONE MARROW-DERIVED MESENCHYMAL STEM CELLS MARKET, BY REGION, 2021–2028 (USD MILLION)            87

TABLE 25           NORTH AMERICA: BONE MARROW-DERIVED MESENCHYMAL STEM CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)             87

TABLE 26           EUROPE: BONE MARROW-DERIVED MESENCHYMAL STEM CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)          88

TABLE 27           ASIA PACIFIC: BONE MARROW-DERIVED MESENCHYMAL STEM CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)             88

6.4         PLACENTA/UMBILICAL CORD-DERIVED MESENCHYMAL STEM CELLS              88

6.4.1      LOW CHANCES OF REJECTION FROM IMMUNE SYSTEM TO PROPEL GROWTH          88

TABLE 28           PLACENTA/UMBILICAL CORD-DERIVED MESENCHYMAL STEM CELLS MARKET, BY REGION, 2021–2028 (USD MILLION)   89

TABLE 29           NORTH AMERICA: PLACENTA/UMBILICAL CORD-DERIVED MESENCHYMAL STEM CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)          89

TABLE 30           EUROPE: PLACENTA/UMBILICAL CORD-DERIVED MESENCHYMAL STEM CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)          90

TABLE 31           ASIA PACIFIC: PLACENTA/UMBILICAL CORD-DERIVED MESENCHYMAL STEM CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)          90

6.5         OTHER CELL SOURCES 90

TABLE 32           STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES, BY REGION, 2021–2028 (USD MILLION)       91

TABLE 33           NORTH AMERICA: STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES, BY COUNTRY, 2021–2028 (USD MILLION)           91

TABLE 34           EUROPE: STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES, BY COUNTRY, 2021–2028 (USD MILLION)       91

TABLE 35           ASIA PACIFIC: STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES, BY COUNTRY, 2021–2028 (USD MILLION)           92

7            STEM CELL THERAPY MARKET, BY TYPE            93

7.1         INTRODUCTION            94

TABLE 36           STEM CELL THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)          94

7.2         ALLOGENEIC STEM CELL THERAPY      94

7.2.1      ECONOMICALLY VIABLE AND LESS TIME-CONSUMING—KEY FACTORS DRIVING MARKET GROWTH 94

TABLE 37           ALLOGENEIC STEM CELL THERAPY MARKET, BY REGION, 2021–2028 (USD MILLION)          95

TABLE 38           NORTH AMERICA: ALLOGENEIC STEM CELL THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)         95

TABLE 39           EUROPE: ALLOGENEIC STEM CELL THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    95

TABLE 40           ASIA PACIFIC: ALLOGENEIC STEM CELL THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    96

7.3         AUTOLOGOUS STEM CELL THERAPY    96

7.3.1      LOW RISK OF POST-TREATMENT COMPLICATIONS TO DRIVE GROWTH          96

TABLE 41           AUTOLOGOUS STEM CELL THERAPY MARKET, BY REGION, 2021–2028 (USD MILLION)          97

TABLE 42           NORTH AMERICA: AUTOLOGOUS STEM CELL THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)         97

TABLE 43           EUROPE: AUTOLOGOUS STEM CELL THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    97

TABLE 44           ASIA PACIFIC: AUTOLOGOUS STEM CELL THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)            98

8            STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION              99

8.1         INTRODUCTION            100

TABLE 45           STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2021–2028 (USD MILLION)           100

8.2         MUSCULOSKELETAL DISORDERS          100

8.2.1      INCREASING CASES OF OSTEOARTHRITIS TO DRIVE MARKET  100

TABLE 46           STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2021–2028 (USD MILLION)       101

TABLE 47           NORTH AMERICA: STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)              101

TABLE 48           EUROPE: STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)              101

TABLE 49           ASIA PACIFIC: STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)              102

8.3         WOUNDS & SURGERIES 102

8.3.1      INCREASING BENEFITS OF ALLOGENEIC-BASED THERAPIES TO SUPPORT MARKET GROWTH    102

TABLE 50           STEM CELL THERAPY MARKET FOR WOUNDS & SURGERIES, BY REGION, 2021–2028 (USD MILLION)       103

TABLE 51           NORTH AMERICA: STEM CELL THERAPY MARKET FOR WOUNDS & SURGERIES, BY COUNTRY, 2021–2028 (USD MILLION)           103

TABLE 52           EUROPE: STEM CELL THERAPY MARKET FOR WOUNDS & SURGERIES, BY COUNTRY, 2021–2028 (USD MILLION)    103

TABLE 53           ASIA PACIFIC: STEM CELL THERAPY MARKET FOR WOUNDS & SURGERIES, BY COUNTRY, 2021–2028 (USD MILLION)    104

8.4         INFLAMMATORY & AUTOIMMUNE DISEASES    104

8.4.1      INCREASING CLINICAL TRIALS TO SUPPORT MARKET GROWTH              104

TABLE 54           STEM CELL THERAPY MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY REGION, 2021–2028 (USD MILLION)           104

TABLE 55           NORTH AMERICA: STEM CELL THERAPY MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)          105

TABLE 56           EUROPE: STEM CELL THERAPY MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)    105

TABLE 57           ASIA PACIFIC: STEM CELL THERAPY MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)          105

8.5         CARDIOVASCULAR DISEASES   106

8.5.1      INCREASING PUBLIC & PRIVATE FUNDING FOR CVD RESEARCH TO DRIVE MARKET 106

TABLE 58           STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2021–2028 (USD MILLION)           106

TABLE 59           NORTH AMERICA: STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 106

TABLE 60           EUROPE: STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 107

TABLE 61           ASIA PACIFIC: STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 107

8.6         NEUROLOGICAL DISORDERS    107

8.6.1      RISING PREVALENCE OF NEUROLOGICAL DISORDERS TO PROPEL MARKET            107

TABLE 62           STEM CELL THERAPY MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2021–2028 (USD MILLION)       108

TABLE 63           NORTH AMERICA: STEM CELL THERAPY MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 108

TABLE 64           EUROPE: STEM CELL THERAPY MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)   108

TABLE 65           ASIA PACIFIC: STEM CELL THERAPY MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 109

8.7         OTHER THERAPEUTIC APPLICATIONS 109

TABLE 66           STEM CELL THERAPY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 109

TABLE 67           NORTH AMERICA: STEM CELL THERAPY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)              110

TABLE 68           EUROPE: STEM CELL THERAPY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)              110

TABLE 69           ASIA PACIFIC: STEM CELL THERAPY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)              110

9            STEM CELL THERAPY MARKET, BY REGION       111

9.1         INTRODUCTION            112

TABLE 70           STEM CELL THERAPY MARKET, BY REGION, 2021–2028 (USD MILLION)          112

9.2         NORTH AMERICA          113

FIGURE 27         NORTH AMERICA: STEM CELL THERAPY MARKET SNAPSHOT              113

TABLE 71           NORTH AMERICA: STEM CELL THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    114

TABLE 72           NORTH AMERICA: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021–2028 (USD MILLION)       114

TABLE 73           NORTH AMERICA: STEM CELL THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)          114

TABLE 74           NORTH AMERICA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2021–2028 (USD MILLION)            115

9.2.1      US         115

9.2.1.1   Increase in stem cell therapy approvals to drive market 115

TABLE 75           US: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021–2028 (USD MILLION)     116

TABLE 76           US: STEM CELL THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)          116

TABLE 77           US: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2021–2028 (USD MILLION)           116

9.2.2      CANADA            117

9.2.2.1   Increase in research activities targeted toward stem cell therapies to propel market              117

TABLE 78           CANADA: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021–2028 (USD MILLION)          117

TABLE 79           CANADA: STEM CELL THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 118

TABLE 80           CANADA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2021–2028 (USD MILLION)           118

9.2.3      RECESSION IMPACT ON NORTH AMERICAN STEM CELL THERAPY MARKET            118

9.3         EUROPE             119

TABLE 81           EUROPE: STEM CELL THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)     119

TABLE 82           EUROPE: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021–2028 (USD MILLION)          119

TABLE 83           EUROPE: STEM CELL THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 120

TABLE 84           EUROPE: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2021–2028 (USD MILLION)           120

9.3.1      GERMANY         120

9.3.1.1   Increasing incidence of sports-related injuries to drive market   120

TABLE 85           GERMANY: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021–2028 (USD MILLION)          121

TABLE 86           GERMANY: STEM CELL THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 121

TABLE 87           GERMANY: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2021–2028 (USD MILLION)           121

9.3.2      UK         122

9.3.2.1   Rising adoption of cell-based therapies to propel market            122

TABLE 88           UK: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021–2028 (USD MILLION)     122

TABLE 89           UK: STEM CELL THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)          122

TABLE 90           UK: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2021–2028 (USD MILLION)           123

9.3.3      FRANCE             123

9.3.3.1   Rising R&D expenditure for stem cell therapy to support market growth  123

TABLE 91           FRANCE: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021–2028 (USD MILLION)          124

TABLE 92           FRANCE: STEM CELL THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 124

TABLE 93           FRANCE: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2021–2028 (USD MILLION)           124

9.3.4      ITALY   125

9.3.4.1   Rising prevalence of neurological and cardiovascular disorders to drive market              125

TABLE 94           ITALY: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021–2028 (USD MILLION)     125

TABLE 95           ITALY: STEM CELL THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 125

TABLE 96           ITALY: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2021–2028 (USD MILLION)           126

9.3.5      SPAIN   126

9.3.5.1   Rising prevalence of CVD to propel market   126

TABLE 97           SPAIN: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021–2028 (USD MILLION)     127

TABLE 98           SPAIN: STEM CELL THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 127

TABLE 99           SPAIN: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2021–2028 (USD MILLION)           127

9.3.6      REST OF EUROPE           128

TABLE 100         REST OF EUROPE: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021–2028 (USD MILLION)       128

TABLE 101         REST OF EUROPE: STEM CELL THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)          128

TABLE 102         REST OF EUROPE: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2021–2028 (USD MILLION)            129

9.3.7      RECESSION IMPACT ON EUROPEAN STEM CELL THERAPY MARKET              129

9.4         ASIA PACIFIC    130

FIGURE 28         ASIA PACIFIC: STEM CELL THERAPY MARKET SNAPSHOT              130

TABLE 103         ASIA PACIFIC: STEM CELL THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)          131

TABLE 104         ASIA PACIFIC: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021–2028 (USD MILLION)       131

TABLE 105         ASIA PACIFIC: STEM CELL THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)     131

TABLE 106         ASIA PACIFIC: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2021–2028 (USD MILLION)            132

9.4.1      JAPAN  132

9.4.1.1   Growing geriatric population and faster regulatory approval process to augment market growth     132

TABLE 107         JAPAN: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021–2028 (USD MILLION)     133

TABLE 108         JAPAN: STEM CELL THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 133

TABLE 109         JAPAN: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2021–2028 (USD MILLION)           133

9.4.2      SOUTH KOREA 134

9.4.2.1   Presence of major players to support market growth in South Korea        134

TABLE 110         SOUTH KOREA: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021–2028 (USD MILLION)       134

TABLE 111         SOUTH KOREA: STEM CELL THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)     134

TABLE 112         SOUTH KOREA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2021–2028 (USD MILLION)            135

9.4.3      INDIA   135

9.4.3.1   Rising incidence of neurodegenerative disorders and diabetes to drive market              135

TABLE 113         INDIA: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021–2028 (USD MILLION)     136

TABLE 114         INDIA: STEM CELL THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 136

TABLE 115         INDIA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2021–2028 (USD MILLION)           136

9.4.4      CHINA  137

9.4.4.1   Increasing investments in stem cell research to drive market      137

TABLE 116         CHINA: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021–2028 (USD MILLION)          137

TABLE 117         CHINA: STEM CELL THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 137

TABLE 118         CHINA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2021–2028 (USD MILLION)           138

9.4.5      REST OF ASIA PACIFIC  138

TABLE 119         REST OF ASIA PACIFIC: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021–2028 (USD MILLION)           138

TABLE 120         REST OF ASIA PACIFIC: STEM CELL THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)             139

TABLE 121         REST OF ASIA PACIFIC: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2021–2028 (USD MILLION)            139

9.4.6      RECESSION IMPACT ON ASIA PACIFIC STEM CELL THERAPY MARKET              139

9.5         REST OF THE WORLD   140

TABLE 122         REST OF THE WORLD: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021–2028 (USD MILLION)       140

TABLE 123        REST OF THE WORLD: STEM CELL THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)          140

TABLE 124         REST OF THE WORLD: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2021–2028 (USD MILLION)            141

9.5.1      RECESSION IMPACT ON REST OF THE WORLD STEM CELL THERAPY MARKET            141

10          COMPETITIVE LANDSCAPE       142

10.1       INTRODUCTION            142

10.2       STRATEGIES ADOPTED BY KEY PLAYERS           143

FIGURE 29         STEM CELL THERAPY MARKET: STRATEGIES ADOPTED BY KEY PLAYERS           143

10.3       REVENUE SHARE ANALYSIS       144

FIGURE 30         REVENUE ANALYSIS OF TOP PLAYERS, 2020−2022 (USD MILLION)          144

10.4       MARKET SHARE ANALYSIS         144

FIGURE 31         STEM CELL THERAPY MARKET: MARKET SHARE ANALYSIS, BY KEY PLAYER, 2022          145

TABLE 125         STEM CELL THERAPY MARKET: INTENSITY OF COMPETITIVE RIVALRY            145

10.5       COMPANY EVALUATION MATRIX          146

FIGURE 32         STEM CELL THERAPY MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022            147

10.5.1    STARS  147

10.5.2    EMERGING LEADERS    147

10.5.3    PERVASIVE PLAYERS     148

10.5.4    PARTICIPANTS 148

10.6       COMPETITIVE BENCHMARKING OF KEY PLAYERS         148

TABLE 126         THERAPEUTIC APPLICATION FOOTPRINT OF COMPANIES              148

10.7       REGIONAL FOOTPRINT OF TOP 15 COMPANIES             149

TABLE 127         REGIONAL FOOTPRINT OF COMPANIES             149

10.8       STARTUP/SME EVALUATION MATRIX   150

FIGURE 33         STEM CELL THERAPY MARKET: STARTUP/SME EVALUATION MATRIX, 2022    150

10.8.1    PROGRESSIVE COMPANIES       151

10.8.2    RESPONSIVE COMPANIES          151

10.8.3    DYNAMIC COMPANIES 151

10.8.4    STARTING BLOCKS       151

10.9       COMPETITIVE BENCHMARKING OF STARTUPS/SMES   152

TABLE 128         STEM CELL THERAPY MARKET: PRODUCT FOOTPRINT ANALYSIS OF STARTUPS/SMES 152

TABLE 129         STEM CELL THERAPY MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES  154

10.10     COMPETITIVE SCENARIOS AND TRENDS           155

10.10.1  PRODUCT APPROVALS 155

TABLE 130         STEM CELL THERAPY MARKET: PRODUCT APPROVALS, JANUARY 2020–OCTOBER 2023  155

10.10.2  DEALS  155

TABLE 131         STEM CELL THERAPY MARKET: DEALS, JANUARY 2020–OCTOBER 2023 155

10.10.3  OTHER DEVELOPMENTS           156

TABLE 132         STEM CELL THERAPY MARKET: OTHER DEVELOPMENTS, JANUARY 2020–OCTOBER 2023  156

11          COMPANY PROFILES    157

(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*

11.1       KEY PLAYERS   157

11.1.1    SMITH+NEPHEW           157

TABLE 133         SMITH+NEPHEW: BUSINESS OVERVIEW             157

FIGURE 34         SMITH+NEPHEW: COMPANY SNAPSHOT (2022) 158

11.1.2    MEDIPOST        160

TABLE 134         MEDIPOST: BUSINESS OVERVIEW          160

FIGURE 35         MEDIPOST: COMPANY SNAPSHOT (2021)           160

11.1.3    JCR PHARMACEUTICALS CO., LTD.        164

TABLE 135         JCR PHARMACEUTICALS CO., LTD.: BUSINESS OVERVIEW              164

FIGURE 36         JCR PHARMACEUTICALS CO., LTD: COMPANY SNAPSHOT (2022)   165

11.1.4    TAKEDA PHARMACEUTICAL COMPANY LIMITED          167

TABLE 136         TAKEDA PHARMACEUTICAL COMPANY LIMITED: BUSINESS OVERVIEW        167

FIGURE 37         TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2022)          168

11.1.5    ANTEROGEN CO., LTD. 170

TABLE 137         ANTEROGEN CO., LTD.: BUSINESS OVERVIEW  170

11.1.6    CORESTEM, INC.            171

TABLE 138         CORESTEM INC.: BUSINESS OVERVIEW 171

FIGURE 38         CORESTEM INC.: COMPANY SNAPSHOT (2021)  171

11.1.7    PHARMICELL CO., LTD 173

TABLE 139         PHARMICELL CO., LTD: BUSINESS OVERVIEW   173

11.1.8    NUVASIVE, INC.              175

TABLE 140         NUVASIVE, INC.: BUSINESS OVERVIEW  175

FIGURE 39         NUVASIVE, INC.: COMPANY SNAPSHOT (2022)  176

11.1.9    RTI SURGICAL  177

TABLE 141         RTI SURGICAL: BUSINESS OVERVIEW    177

11.1.10  ALLOSOURCE   178

TABLE 142         ALLOSOURCE: BUSINESS OVERVIEW     178

11.1.11  HOLOSTEM TERAPIE AVANZATE SRL    179

TABLE 143         HOLOSTEM TERAPIE AVANZATE SRL: BUSINESS OVERVIEW              179

11.1.12  ORTHOFIX MEDICAL INC.          180

TABLE 144         ORTHOFIX MEDICAL INC.: BUSINESS OVERVIEW            180

FIGURE 40         ORTHOFIX MEDICAL INC.: COMPANY SNAPSHOT (2022)              181

11.1.13  STEMPEUTICS RESEARCH PVT LTD.      182

TABLE 145         STEMPEUTICS RESEARCH PVT LTD.: BUSINESS OVERVIEW              182

11.1.14  REGROW BIOSCIENCES PVT LTD.          184

TABLE 146         REGROW BIOSCIENCES PVT LTD.: BUSINESS OVERVIEW              184

11.2       OTHER PLAYERS           185

11.2.1    ATHERSYS, INC.             185

TABLE 147         ATHERSYS, INC.: BUSINESS OVERVIEW 185

11.2.2    MESOBLAST LTD.          186

TABLE 148         MESOBLAST LTD.: BUSINESS OVERVIEW            186

11.2.3    BIORESTORATIVE THERAPIES, INC.       188

TABLE 149         BIORESTORATIVE THERAPIES, INC.: BUSINESS OVERVIEW              188

11.2.4    PLURISTEM THERAPEUTICS INC.           189

TABLE 150         PLURISTEM THERAPEUTICS INC.: BUSINESS OVERVIEW              189

11.2.5    BRAINSTORM CELL LIMITED    190

TABLE 151         BRAINSTORM CELL LIMITED: BUSINESS OVERVIEW      190

11.2.6    GAMIDA CELL  191

TABLE 152         GAMIDA CELL: BUSINESS OVERVIEW    191

11.2.7    VIACYTE, INC.  192

TABLE 153         VIACYTE, INC.: BUSINESS OVERVIEW    192

11.2.8    KANGSTEM BIOTECH CO., LTD.             193

TABLE 154         KANGSTEM BIOTECH CO., LTD.: BUSINESS OVERVIEW 193

11.2.9    HOPE BIOSCIENCES      194

TABLE 155         HOPE BIOSCIENCES: BUSINESS OVERVIEW        194

11.2.10  CELLULAR BIOMEDICINE GROUP          195

TABLE 156         CELLULAR BIOMEDICINE GROUP: BUSINESS OVERVIEW              195

11.2.11  PERSONALIZED STEM CELLS    196

TABLE 157         PERSONALIZED STEM CELLS: BUSINESS OVERVIEW      196

*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

12          APPENDIX         197

12.1       DISCUSSION GUIDE      197

12.2       KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL             200

12.3       CUSTOMIZATION OPTIONS      201

12.4       RELATED REPORTS       202

12.5       AUTHOR DETAILS         203